We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01465152
First Posted: November 4, 2011
Last Update Posted: February 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Novo Nordisk A/S
  Purpose
This trial is conducted in Europe. The aim of this trial is to compare the efficacy of metformin and repaglinide used alone or combined administered as initial treatment in subjects with type 2 diabetes in which diet and exercise have failed.

Condition Intervention Phase
Diabetes Diabetes Mellitus, Type 2 Drug: metformin Drug: repaglinide Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentre, Randomised, Comparative, Open, Three Armed Parallel Group Study on the Use of Metformin, Repaglinide or the Combination of Both in Type 2 Diabetic Patients After Failure of Dietary Measures

Resource links provided by NLM:


Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Change of % HbA1c (glycosylated haemoglobin) in blood

Secondary Outcome Measures:
  • Change of the mean body mass index calculated as weight in kilograms divided by the square of height in metres
  • Incidence of clinical and/or biochemistry hypoglycaemia episodes
  • Incidence of adverse events
  • Presence of laboratory abnormalities in routine blood analyses
  • Change of the blood pressure and/or heart rate
  • Treatment compliance

Enrollment: 182
Actual Study Start Date: March 6, 2002
Study Completion Date: October 21, 2004
Primary Completion Date: October 21, 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Met Drug: metformin
Adminstered orally during the three main meals for 24 weeks
Active Comparator: Rep Drug: repaglinide
Administered orally before the three main meals for 24 weeks
Active Comparator: Met+Rep Drug: metformin
Adminstered orally during the three main meals for 24 weeks
Drug: repaglinide
Administered orally before the three main meals for 24 weeks

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with type 2 diabetes
  • Treated by diet for at least 3 months
  • Never treated with hypoglycaemic drugs
  • HbA1c (glycaemic haemoglobin A1c) on inclusion time superior to 6.5%

Exclusion Criteria:

  • Very symptomatic diabetes
  • Advanced vascular complications
  • Manifest renal failure
  • Manifest hepatic disease
  • Pregnancy, breast feeding or intention to become pregnant or if it is considered that the patient is not using adequate contraceptive measures. Adequate contraceptive measures are considered to be an intrauterine device, oral contraceptives and barrier methods
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01465152


Locations
Spain
Novo Nordisk Investigational Site
Barcelona, Spain, 08020
Novo Nordisk Investigational Site
Benamargosa, Spain, 29718
Novo Nordisk Investigational Site
Burlada, Spain, 31600
Novo Nordisk Investigational Site
Camas, Spain, 41900
Novo Nordisk Investigational Site
Fuenlabrada, Spain, 28942
Novo Nordisk Investigational Site
Gijón, Spain, 33212
Novo Nordisk Investigational Site
Granada, Spain, 18012
Novo Nordisk Investigational Site
Lugo, Spain, 27004
Novo Nordisk Investigational Site
Madrid, Spain, 28021
Novo Nordisk Investigational Site
Madrid, Spain, 28030
Novo Nordisk Investigational Site
Madrid, Spain, 28035
Novo Nordisk Investigational Site
Portugalete, Spain, 48920
Novo Nordisk Investigational Site
San Adria del Besos, Spain, 08930
Novo Nordisk Investigational Site
Santander, Spain, 39009
Novo Nordisk Investigational Site
Santander, Spain, 39011
Novo Nordisk Investigational Site
Tegueste, Spain, 38280
Novo Nordisk Investigational Site
Valencia, Spain, 46021
Novo Nordisk Investigational Site
Zaragoza, Spain, 50007
Sponsors and Collaborators
Novo Nordisk A/S
Investigators
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S
ClinicalTrials.gov Identifier: NCT01465152     History of Changes
Other Study ID Numbers: AGEE-1411
First Submitted: October 31, 2011
First Posted: November 4, 2011
Last Update Posted: February 20, 2017
Last Verified: February 2017

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Repaglinide
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs